Navigation Links
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Date:3/25/2008

atements. Some factors that may affect these forward-looking statements include, but are not limited to, delays in the completion of our clinical trials, clinical failure at later stages of development and undesirable effects from our product candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
5. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...irstCall/ -- Duska Therapeutics,Inc., (OTC Bulle...itted its,pivotal Phase 3 ATPace clinical trial p...sment (SPA) procedure with the U.S. Food and Drug ...g an agreement with the FDA, Duska intends to init...-controlled and randomized Phase 3,clinical trial...
(Date:11/20/2008)...wire/ -- The Scandinavian-based drug,development ...tudies on its,lead antimicrobial candidate LTX-10...ies showed that the novel lytic peptidomimetic has...ly better towards killing Staphylococcus,aureus a...ard drugs. In,addition to this it has proven effe...
(Date:11/19/2008)...gs on critical enzyme,s regulation may hold key to...orders , , MEMPHIS, Tenn., Nov. 19 /PRNewsw...n,s Research Hospital have gained new insights int...s called calpains. , , As the cell,s molec...ular processes, including the movement of cells in...
(Date:11/18/2008)...ll/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialty...t Company,and Sosei Group Corporation ("Sosei"; ... biopharmaceutical company, today announce that Ne...inical efficacy data for NSL-043/SD118.,This inve...athic pain and has,successfully completed Phase I...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 1Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 2Low Vitamin D Levels May Boost Mens Heart Attack Risk 21362 1Phase 3 results for alogliptin 21359 1Phase 3 results for alogliptin 21359 2Phase 3 results for alogliptin 21359 3Public Invited to Learn to Work Safe Live Well During Safety Day n June 11 21356 1
...d Stability,Significantly Longer than Placebo and ...e with Placebo , MARIETTA, Ga. and COLLEGEVILLE, P...yeth Pharmaceuticals, a division of Wyeth,(NYSE:WY...lts on,bifeprunox, an investigational treatment fo...ay at the 2007 annual meeting of,the American Psyc...
...e as Future-Generation,Technology, BARCELONA, Spai...oday announced positive results from ABSORB, the w...and performance of a fully,bioabsorbable drug elut...rtery disease. Nine-month results from the first 3...roPCR meeting,demonstrated no stent thrombosis an...
Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3
(Date:11/22/2008)...cipes to cut fat, salt a quick fix without losing ... (HealthDay News) -- You can eat healthier this ho...ood choices, say experts with the Texas AgriLife E...he sugar, fat or salt content of almost any holida... nutrition specialist Mary Bielamowicz said in a n...
(Date:11/21/2008)...ts and schools need to work together to stop abusi.... 21 (HealthDay News) -- Behavior that was once di...bullying. , And as mounting research shows the ... mental-health professionals, schools, parents and...to combat this threatening behavior. , "Bullyi...
(Date:11/21/2008)...olo., Nov. 21 Heska Corp... present at the New York Society of,Security Anal...ference on,December 2, 2008 at 1177 Avenue of the...ation is scheduled to begin at 9:35 a.m. Eastern T...le via live webcast and for two weeks,following t...
(Date:11/21/2008)...ht one day lead to a novel technique to combat can...(HealthDay News) -- Belgian researchers have disco...ad of sugar for food, and this might lead to new t...o survive and proliferate, all cells in the body n...ar [glucose], a process that requires oxygen. Comp...
Breaking Medicine News(10 mins):Health News:Substitutions Make Holiday Fare Healthier 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:New Approach Keeps Tumor Cells From Refueling 2
...to produce more antibiotics by the Infectious Dise...ation// is being encouraged to provide drug compan...resistant microbes should deserve the utmost prior.... No anti-biotics have so far been developed to tr...
... Michelle Hindin has revealed that adolescents who...re at an increased risk// of developing depressive...ll the respondents reported witnessing parental do...male adolescents and 1 in 5 female adolescents wis...
...ization to investigate the possibility of building...bird flu//. They are already ready to invest $1.9b...tigation with bird flu virus is already being done...the House of Commons about the UK's preparedness f...
...atment (chemotherapy) given to patients with disor... treatment// of the much dreaded bird flu. The tr...nteers. An immune system disorder referred to as h...H) is similar in a lot of ways to the bird flu inf...
Other Medicine News:Health News:Anti-Cancer Treatment Promises Hope in Bird Flu Treatment 2
Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide
Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide
Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi
Selecta Trio The pinnacle in the family, combining the Nd:YAG, diode-pumped solid-state (DPSS) 532 Photocoagulator and Q-switched frequency-doubled 532nm laser (SLT) and offering maximum flexibility
Medicine Products: